权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Regulation of Gene Expression in Cartilage

软骨基因表达的调控

基本信息

批准号：
7485887
负责人：
LINDA J SANDELL
金额：
$ 0.86万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-01 至 2010-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7485887
关键词：
Adipose tissue Adult Alternative Splicing Appendix Applications Grants Binding Biological Models CCAAT-Enhancer-Binding Proteins Cartilage Cells Chick Embryo Child Chondrocytes Chondrogenesis Clinical Trials Collaborations Collagen Gene Data Development Development Plans Disease Dorsal EWS/FLI 1 Type 1 antisense oligonucleotide Embryo Excision Exons Extracellular Matrix Face Family member Gene Expression Gene Expression Regulation Genes Genetic Transcription Grant Health Heterogeneous Nuclear RNA In Vitro Inflammation Inflammatory Instruction Interleukin-1 Intervertebral disc structure Laboratories Length Literature Maintenance Mediating Mesenchymal Messenger RNA Methods Minority Monitor NF-kappa B Nuclear Numbers Osteogenesis Peptide Elongation Factor 1 Phase Play Procollagen Production Progress Reports Protein Isoforms Proteins Publications RNA Sequences RNA Splicing RNA-Binding Proteins Regulation Reporter Research Research Design Resources Role Safety Signal Transduction Skeletal Development Staging Stem cells System TFAP2A gene Testing Trans-Activators Translations Type II Procollagen Undifferentiated Vertebrates Woman Work Xenopus bone morphogenetic protein 2 bone morphogenetic protein 4 cytokine enhancer-binding protein AP-2 human subject in vivo mRNA Precursor notochord novel strategies repaired response transcription factor

项目摘要

............... 5 Other Biographical Sketches (Not to exceed four pages for each - See instructions)) ............................ 9 Resources ......................................................................................................................................................... 19 Research Plan Introduction to Revised Application (Not to exceed 3 pages) ................................................................................................................ Introduction to Supplemental Application (Not to exceed one page) .................................................................................................... A. Specific Aims ............................................................................. _ ....................................................................... :................. 20 / r-- B. Background and Significance ........................................................ I"........................................................................................ I'" C. Preliminary Studies/Progress Report/ _.- (Items A-D: not to exceed 25 pages*) ._ Phase I Progress Report (SBIPJSTTR Phase II ONLY) I* SBIR/STTR Phase I: Items A-D limited to 15 pages. I I I D. Research Design and Methods ............................................... _ ......................................................................................... E. Human Subjects .......................................................................................................................................................................... Protection of Human Subjects (Required if Item 4 on the Face Page is marked "Yes") Inclusion of Women (Required if Item 4 on the Face Page is marked "Yes") ...................................................................... Inclusion of Minorities (Required if Item 4 on the Face Page is marked "Yes") .................................................................... Inclusion of Children (Required if Item 4 on the Face Page is marked "Yes") ...................................................................... Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked "Yes" and a Phase I, II, or III clinical trial is proposed ............................................................................................................................................................... F. Vertebrate Animals ..................................................................................................................................................................... G. Literature Cited ............................................................................................................................................................................ H. Consortium/Contractual Arrangements ...................................................................................................................................... I. Consultants ................................................................................................................................................................................. J. Product Development Plan (SBIR/STTR Phase II and Fast-Track ONLY) ............................................................................... Checklist .......................................................... ................................................................................................. Appendix (Five collated sets. No page numbering necessary for Appendix.) Check if Appendix is Included Appendices NOT PERMITTED for Phase I SBIR/S TTR unless specifically solicited. Number of publicaEExis and manusoripts acoepted for publication (not to exceed 10) 10 Other items (list):

............... 5 其他个人简历（每份不超过四页-见说明）... 9 资源......................................................................................................................................................... 19 研究计划经修订的申请简介（不超过3页）............................................................................................................................................................................................................................................... 补充申请简介（不超过一页）....... a.具体目标... _ ....................................................................... :................. 20 /r-- B。背景和意义......本人"........我" C.初步研究/进度报告/_. -（项目A-D：不超过25页 *）。第I阶段进度报告（仅限SBIPJSTTR第II阶段）I * SBIR/STTR第I阶段：A-D项限制为15页。我我我 D.研究设计和方法..... _ ......................................................................................... e.人类受试者.......................................................................................................................................................................... 人类受试者保护（如果正面页面上的第4项标记为"是"，则需要）纳入女性（如果正面页面上的项目4标记为"是"，则需要）... 纳入少数群体（如果正面页项目4标记为"是"，则需要）.... 纳入儿童（如果正面页上的第4项标记为"是"，则需要）..... 数据和安全性监测计划（如果正面页面上的第4项标记为"是"，则需要提供I、II或III期临床试验）建议试用............................................................................................................................................................... F.脊椎动物..................................................................................................................................................................... G.引用的文献............................................................................................................................................................................ H.联合体/合同安排...... I.顾问................................................................................................................................................................................. J.产品开发计划（仅限SBIR/STTR阶段II和快速通道）.... 核对表................... ................................................................................................. 附录（五个整理集。附录无需页码。）检查是否阑尾是包括附录不允许用于I期SBIR/S TTR，除非特别要求。接受出版的出版物和手册数量（不超过10份）10 其他项目（列表）：